Document:

SETTLEMENT
AGREEMENT

 

This
Settlement Agreement (hereinafter “Agreement”) dated September 30, 2019 is entered into by and between
Southwest Capital Funding, Ltd. A Texas Limited Partnership (“Southwest”) and Greenway Technologies, Inc. f/k/a UMED
Holdings Inc. (“Greenway”) (Southwest and Greenway are referred to individually as a “Party” and collectively
herein as the “Parties”).

 

RECITALS:

 

WHEREAS,
Southwest and Greenway are parties to a lawsuit pending in Hawaii, cause no. 16-1-0342, in the Circuit Court of the Third Circuit,
State of Hawaii, styled Southwest Capital Funding, Ltd. v. Mamaki Tea, Inc., et. al. (the “Lawsuit”).

 

WHEREAS,
without admission, including liability, and to avoid the time, cost and uncertainty of continued litigation, Southwest and Greenway,
for sufficient consideration, including the mutual covenants in this agreement, intend to fully and finally compromise and settle
all claims between them to the date of this agreement, all as more particularly hereinafter provided.

 

NOW
THEREFORE, for the consideration stated herein and the mutual promises and agreements set forth herein, the Parties hereby agree
as follows:

 

A.
SETTLEMENT

 

		1.	The
                                         Parties agree to the entry of a Stipulated Judgment in the Lawsuit, with Southwest awarded
                                         judgment against Greenway in the amount of $740,000.00, in the form attached hereto as
                                         Exhibit A.

 

		2.	Greenway
                                         agrees to provide Southwest a Promissory Note in the amount of $525,000.00, providing
                                         for a three-year term, at 7.7% simple interest-only payable semi-annually, with interest
                                         due calculated on a 365-day year, default interest at 18%, with the principal amount
                                         due at maturity. A copy of the Promissory Note is attached hereto as Exhibit B.

 

		3.	Greenway
                                         agrees to issue and deliver to Southwest 1,000,000 shares of Rule 144 restricted Class
                                         A common stock valued at $0.05 per share ($50,000.00 – Income to Southwest/Expense
                                         to GWTI), such restrictive legend providing no longer than the statutory six (6) months
                                         restrictions. However, provided there is no default on the Promissory Note, Southwest
                                         agrees to not sell any stock for at least one year from the date of this Agreement. An
                                         event of default under this Settlement Agreement shall be created and exist in the event
                                         that Greenway no longer has any securities registered pursuant to Section 12(a) of the
                                         Securities Exchange Act of 1934, as amended.

 

		4.	Southwest
                                         agrees to not domesticate, abstract, execute, and/or otherwise attempt to enforce the
                                         Stipulated Judgment until such time as Greenway fails to make a payment on the Promissory
                                         Note as the same shall become due and payable, and Southwest gives written notice of
                                         such default to Greenway and/or their counsel, and such failure continues unremedied
                                         for five business days thereafter. In all events, Greenway is entitled to a credit against
                                         the Stipulated Judgment for any payment made towards the Promissory Note and a $50,000
                                         credit for the stock delivered pursuant to paragraph 3.

 

    	SETTLEMENT AGREEMENT – Page 1	 

    	 

    

 

		5.	Upon
                                         receipt of payment of all amounts due under the Promissory Note, Southwest agrees to
                                         release Greenway from all obligations arising under the Stipulated Judgment and to execute
                                         and deliver to Greenway a Release of Judgment.

 

B.
RELEASE

 

		1.	For
                                         the consideration stated herein, and except for the Stipulated Judgment and the obligations
                                         undertaken by the parties in this Settlement Agreement and Promissory Note, Southwest,
                                         for itself, its officers, shareholders, directors, agents, assigns, successors, and representatives,
                                         hereby releases all claims of whatever nature, known or unknown, which it may have against
                                         Greenway, its officers, shareholders, directors, agents, assigns, successors, and representatives,
                                         which claims arise from occurrences to the date of this agreement, including without
                                         limitation, the suit described herein

 

		2.	For
                                         the consideration stated herein, Greenway for itself, its officers, shareholders, directors,
                                         agents, assigns, successors, and representatives, hereby releases all claims of whatever
                                         nature, known or unknown, which it may have against Southwest, its officers, shareholders,
                                         directors, agents, assigns, successors, and representatives, which claims arise from
                                         occurrences to the date of this agreement, including without limitation, the suit described
                                         herein.

 

C.
REPRESENTATIONS AND WARRANTIES

 

		1.	As
                                         a material inducement to the Parties’ entry into this agreement, each Party unconditionally
                                         represents that at the signing of this agreement and delivery of any documents hereunder:

 

		i.	such
                                         Party has the right and power to enter into this agreement;

 

		ii.	this
                                         agreement and all other agreements delivered in connection with this agreement have been
                                         or will be duly executed by and delivered by such Party and are valid and binding agreements
                                         of such Party enforceable against such Party in accordance with their respective terms;

 

		iii.	execution
                                         and delivery of this agreement and all other documents delivered in connection herewith
                                         will not conflict with or result in a breach of any of the terms, conditions, or provisions
                                         of or constitute a default under any other agreement or instrument to which such Party
                                         is a Party or by which such Party is bound or by any law, statute, regulation, rule,
                                         order, writ, injunction, or decree of any governmental instrumentality or court;

 

    	SETTLEMENT AGREEMENT – Page 2	 

    	 

    

 

		iv.	such
                                         Party, as such Party’s interest may appear, has complete and unrestricted power
                                         to sell, transfer, assign, and deliver to the other the interests and release under this
                                         and other documents delivered hereunder; and

 

		v.	such
                                         Party is the owner and holder of all claims and causes of action released in paragraph
                                         3 and has not previously assigned, in whole or in part (by operation of law or otherwise)
                                         any such claims or interests.

 

		2.	The
                                         Parties shall hold each other harmless and indemnify each of them and their officers,
                                         directors, shareholders, agents, assigns, heirs, successors, and representatives from
                                         liability and loss from, and the cost of defense (including without limitation, reasonable
                                         attorneys’ and accountants’ fees) of claims arising from breach, failure
                                         or falsity of representations and warranties in this agreement, or from the claims of
                                         third parties brought over one of the Parties against another.

 

D.
GENERAL CONDITIONS

 

		1.	This
                                         agreement shall be governed and construed in accordance with the laws of the State of
                                         Texas, enforcement of which by suit on claims arising from breach, failure, or falsity
                                         of representations and warranties as provided for herein shall entitle the successful
                                         party to reasonable and necessary attorneys’ fees, and is payable and performable
                                         in Dallas County, Texas.

 

		2.	The
                                         obligations of the Parties under this agreement shall survive the execution and delivery
                                         of this agreement.

 

		3.	This
                                         agreement is binding on and inures to the benefit of the parties hereto and their respective
                                         heirs, successors, and assigns.

 

		4.	The
                                         Parties shall execute any additional documents that are reasonably necessary to effectuate
                                         or evidence the terms of this agreement.

 

		5.	The
                                         provisions of this Settlement Agreement comprise all the terms, conditions, agreements,
                                         and representations of the parties hereto respecting the subject matter of this Settlement
                                         Agreement which can be modified or amended only in writing signed by the parties. The
                                         Parties represent and acknowledge that each does not rely, has not relied upon, and expressly
                                         disclaims any reliance upon any representation by a party, written or oral, except as
                                         expressly set forth herein.

 

		6.	This
                                         agreement may be executed and evidenced in multiple counterparts.

 

    	SETTLEMENT AGREEMENT – Page 3	 

    	 

    

 

E.
NOTICES

 

Any
notice or payment required to be given under this agreement shall be made by electronic mail to the following addresses:

 

If
to Greenway, notice shall be sent to:

 

 

SIGNED
as of the date first noted above.

 

	Southwest
    Capital Funding, Ltd.	 	Greenway
                                         Technologies, Inc.

        f/k/a
        UMED Holdings Inc.

	 	 	 	 	 
	/s/ S. Kent Hope	 	/s/? Ransom B. Jones
	By	S.
    Kent Hope	 	By	Ransom
    Jones
	Its:	Manager	 	Its:	Chief
    Financial Officer

 

    	SETTLEMENT AGREEMENT – Page 4	 

    	 

    

 

EXHIBIT
A TO SETTLEMENT AGREEMENT

[Stipulated
Judgement approved as to form and when fully executed to be inserted here]

 

	Carlsmith
    Ball LLP	 	 
	Tom
                                         E. Roesser 

        ASB
        Tower, Suite 2100

        1001
        Bishop Street

        Honolulu,
        HI 96813

        Tel
        No. 808.523.2500

        Fax
        No. 808.523.0842

         
	3241	 
	Katherine
                                         A. Garson 

        121
        Waianuenue Avenue

        P.O.
        Box 686

        Hilo,
        HI 96721-0686

        Tel
        No. 808.935.6644

        Fax
        No. 808.935.7975
	5748	 

 

	Attorneys
                                         for Plaintiff

        SOUTHWEST
        CAPITAL FUNDING, LTD.
	 

 

IN
THE CIRCUIT COURT OF THE THIRD CIRCUIT

 

STATE OF HAWAI’I

 

	SOUTHWEST
                                         CAPITAL FUNDING, LTD., a Texas limited partnership,

         

        Plaintiff,

         

        vs.

         

        MAMAKI
        TEA, INC., a Nevada corporation, MAMAKI OF HAWAII, INC., a Nevada corporation, TIMOTHY ANDREW BENKO a.k.a. TIMOTHY A.
        BENKO, MARY ROBERTA CAPONE a.k.a. MARY R. CAPONE a.k.a. MARY T. CAPONE, BANK OF AMERICA, N.A., a national association,
        ROBERT R. ROMER, JOE LACOSTE, CURT BORMAN, UMED HOLDINGS, INC., a Texas corporation, and DOE INDIVIDUALS 1-50, and DOE
        ENTITIES 1-50,
	CIVIL
                                         NO. 16-1-0342

        (Foreclosure)

         

        STIPULATED
        JUDGMENT; ORDER

         

         

         

         

         

         

         

         

         

        No
        Trial Date Set

         

        

        [caption
        continued on next page]

	 

                                                                                Defendants.

                                                                                 
	 
	MAMAKI
                                         TEA, INC., a Nevada corporation; MAMAKI TEA OF HAWAII, INC., a Nevada corporation, and
                                         CURT BORMAN,

                                                                                                                         

        Counterclaimants
        and

        Crossclaimants,

         

        vs.

         

        SOUTHWEST
        CAPITAL FUNDING, LTD., and UMED HOLDINGS, INC.,

         

        Counterclaim
        Defendants and

        Crossclaim
        Defendants.

         
	 
	MAMAKI
                                         TEA, INC., a Nevada corporation, MAMAKI OF HAWAII, INC., a Nevada corporation and CURT
                                         BORMAN,

         

        Third-Party
        Plaintiffs,

         

        vs.

         

        TERRY
        BRAUDRICK and TERRY CHESNUT aka TERRY CHESTNUT,

         

        Third-Party
        Defendants.

         
	 
	TERRY
                                         BRAUDRICK,

                                                                                                                         

        Third-Party
        Defendant/

        Counterclaimant/Third-Party

        Plaintiff,

         

        vs.

         

        MAMAKI
        TEA, INC., a Nevada corporation, MAMAKI OF HAWAII, INC., a Nevada corporation, and CURT BORMAN,

         

        Counterclaim
        Defendants,

         

        and

         

        MAMAKI
        TEA & EXTRACT, INC., a Nevada corporation, HAWAII BEVERAGES, INC., a Nevada corporation and DOES 1-100,

         

        Third-Party
        Defendants.

         
	 

 

    	 	 	 

    	 

    

 

STIPULATED
JUDGMENT

 

IT
IS HEREBY STIPULATED by and between Plaintiff SOUTHWEST CAPITAL FUNDING, LTD. (“Southwest”) and Defendant UMED HOLDINGS,
INC. in Civil No. 16-1-0342, and pursuant to Hawai’i Rules of Civil Procedure Rule 54, that final judgment be entered against
Defendant UMED HOLDINGS, INC. as follows:

 

1.
Judgment is entered in favor of Southwest and against Defendant UMED Holdings, Inc., now known as Greenway Technologies, Inc.,
in the amount of SEVEN HUNDRED FORTY THOUSAND AND NO/100 DOLLARS ($740,000.00) (the “Judgment Amount”).

 

2.
Southwest is also awarded post-judgment interest on the Judgment Amount at the statutory rate of ten percent (10%) per annum from
and after the date of the Court’s approval and entry of this Final Judgment.

 

3.
This Court shall retain jurisdiction in this matter to resolve any dispute arising from this Stipulated Judgment, and shall have
the discretion to award reasonable attorneys’ fees and costs against the non-prevailing party in any such dispute.

 

4.
This Stipulated Judgment may be executed in counterparts, each of which constitutes an original and all of which constitute one
and the same agreement.

 

DATED:
Hilo, Hawai’i, _________________________.

 

	 	 
	 	TOM
                                         E. ROESSER

        KATHERINE
        A. GARSON

	 	 
	 	Attorneys
                                         for Plaintiff

        SOUTHWEST
        CAPITAL FUNDING, LTD.

	 	 
	 	 
	 	 
	 	Attorneys
                                         for Defendant

        Greenway
        Technologies, Inc.

        f/k/a
        UMED Holdings, Inc.

 

APPROVED
AND SO ORDERED:

 

 

 

JUDGE
OF THE ABOVE-ENTITLED COURT

 

SOUTHWEST
CAPITAL FUNDING, LTD. v. MAMAKI TEA, INC., et al., Civil No. 16-1-0342, Circuit Court of the Third Circuit, STIPULATED JUDGMENT;
ORDER

 

    	 	2	 

    	 

    

 

EXHIBIT
B TO SETTLEMENT AGREEMENT

[Promissory
Note approved as to form and when fully executed to be inserted here]

 

PROMISSORY
NOTE

 

$525,000.00

 

	STATE
    OF TEXAS 	§	 
	 	§	 
	COUNTY
    OF DALLAS 	§	 

 

September
26, 2019

 

FOR
VALUE RECEIVED, the undersigned, Greenway Technologies, Inc. f/k/a UMED Holdings Inc. (“Maker”), unconditionally
promises to pay to the order of Southwest Capital Funding, Ltd. (“Holder”) the principal sum of Five Hundred
and Twenty Five Thousand Dollars ($525,000.00), with interest at the rate of 7.7% per annum (calculated on the basis of a 365
day year) on the unpaid principal balance (the “Applicable Rate”). Principal and interest under this note (the “Note”)
are due and payable as follows:

 

Semi-annual
payments of accrued interest shall be due and payable on February 15 and August 15 of each year, with the first such installment
due on February 15, 2020. All principal and any accrued and unpaid interest shall be due and payable on August 15, 2022 (the “Maturity
Date”)

 

At
the option of the holder of this Note, the entire principal balance and accrued interest owing hereon shall at once become due
and payable, without notice or demand, upon the occurrence at any time of any of the following events (“Events of Default”):

 

	 	(1)	failure
    to make prompt payment of any interest hereon when due;
	 	 	 
	 	(2)	the
    termination, dissolution or cessation of the business, or
	 	 	 
	 	(3)	the
    bankruptcy or insolvency of, the assignment for the benefit of creditors by, or an appointment of a receiver for, any of the
    property of any party liable for the payment hereof, whether as maker, endorser, guarantor, surety or otherwise.

 

The
failure to exercise the option to accelerate the maturity hereof upon the happening of any one or more of the Events of Default
specified herein shall not constitute a waiver of the right of the holder hereof to exercise the same or any other option at that
time or at any subsequent time with respect to such uncured default or any other event of uncured default hereunder or under any
instrument securing, governing or evidencing the loan evidenced hereby. The remedies of the holder hereof, as provided herein
and in any instrument securing, governing or evidencing the loan evidenced hereby, shall be cumulative and concurrent and may
be pursued separately, successively or together, as often as occasion therefor shall arise, at the sole discretion of the holder
hereof. The acceptance by the holder hereof of any payment hereon which is less than payment in full of all amounts due and payable
at the time of such payment shall not constitute a waiver of the rights of the holder hereof to exercise the foregoing option
or any other option granted to the holder hereof in this Note or in any other instrument securing, governing or evidencing the
loan evidenced hereby, at that time or at any subsequent time, or nullify any prior exercise of any such option.

 

    	 	 	 

    	 

    

 

After
an Event of Default or after the maturity hereof, the principal hereof and past-due interest hereon shall bear interest at eighteen
percent (18%) per annum.

 

Except
as otherwise expressly provided herein, the undersigned and all other parties now or hereafter liable for the payment hereof,
whether as endorser, guarantor, surety, or otherwise, severally waive demand, presentment, notice of dishonor, notice of intention
to accelerate the indebtedness evidenced hereby, notice of the acceleration of the indebtedness evidenced hereby, diligence in
collecting, grace, notice and protest, and consent to all extensions which from time to time may be granted by the holder hereof
and to all partial payments hereon, whether before or after the maturity hereof.

 

If
this Note is not paid when due, whether at the maturity hereof or by acceleration, or if this Note is collected through a bankruptcy,
probate or other court, whether before or after the maturity hereof, the undersigned agrees to pay all costs of collection, including
but not limited to reasonable attorneys’ fees, incurred by the holder hereof.

 

All
agreements between the undersigned and the holder hereof, whether now existing or hereafter arising and whether written or oral,
are hereby limited so that in no contingency, whether by reason of acceleration of the maturity hereof or otherwise, shall the
interest contracted for, charged, received, paid or agreed to be paid to the holder hereof, exceed the maximum amount permissible
under applicable law. If, from any circumstance whatsoever, interest would otherwise be payable to the holder hereof in excess
of the maximum lawful amount, the interest payable to the holder hereof shall be reduced to the maximum amount permitted under
applicable law; and if from any circumstance the holder hereof shall ever receive anything of value deemed interest by applicable
law in excess of the maximum lawful amount, an amount equal to any excessive interest shall be applied to the reduction of the
principal hereof and not to the payment of interest, or if such excessive interest exceeds the unpaid balance of principal hereof,
such excess shall be refunded to the undersigned. All interest paid or agreed to be paid to the holder hereof shall, to the extent
permitted by applicable law, be amortized, prorated, allocated, and spread throughout the full period until payment in full of
the principal so that the interest hereon for such full period shall not exceed the maximum amount permitted by applicable law.
This paragraph shall control all agreements between the undersigned and the holder hereof.

 

This
Note may be prepaid, in whole or in part, at any time and from time to time, without premium, penalty, or notice. Except as otherwise
specified herein, any prepayment hereon shall be applied first to accrued interest then due hereon and next to the last maturing
installment of principal due hereunder.

 

    	 	 	 

    	 

    

 

Any
notice or other communication required or permitted hereby, or convenient to the holder, shall be deemed delivered when deposited
(a) in a receptacle of the United States Postal Service, as registered or certified mail, return receipt requested, postage prepaid,
or (b) with an expedited courier service, fees prepaid and addressed to the undersigned at its address.

 

All
obligations, covenants, and terms of payment are expressly performable solely in Dallas County, Texas. The substantive laws of
the State of Texas shall govern the validity, construction, enforcement, and interpretation of this Note. In the event of a dispute
involving this Note, the undersigned irrevocably agrees that venue for such dispute shall lie in any court of competent jurisdiction
in Dallas County, Texas.

 

Executed
the date first above written.

 

	 	Maker:
	 	 
	 	Greenway
    Technologies, Inc.
	 	f/k/a
    UMED Holdings Inc.

 

	 	/s/ Ransom B. Jones
	 	By:	Ransom
    Jones
	 	Its:	Chief
    Financial OfficerEX-10.1

 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 1, 2019 by and among
Constellation Pharmaceuticals Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

 RECITALS 
 A.
The Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions of Section 4(a)(2) of the 1933 Act (as defined below), and Rule 506 of
Regulation D (“Regulation D”) as promulgated by the SEC (as defined below) under the 1933 Act; 
 B. The Investors
wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms and subject to the conditions stated in this Agreement, shares (the “Shares”) of the Company’s Common Stock, par value
$0.0001 per share (the “Common Stock”); and 
 C. Contemporaneously with the sale of the Shares, the parties hereto
will execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain
registration rights in respect of the Shares under the 1933 Act and applicable state securities laws. 
 In consideration of the mutual
promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Definitions. For the purposes of this Agreement, the following terms shall have the meanings set forth below: 

“Affiliate” means, with respect to any Person, any other Person which directly or indirectly through one or more
intermediaries Controls, is controlled by, or is under common Control with such Person. 
 “Business Day” means a day,
other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business. 

“Closing” has the meaning set forth in Section 3.1. 

“Closing Date” has the meaning set forth in Section 3.1. 

“Common Stock” has the meaning set forth in the recitals to this Agreement. 

“Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 

 “Company Covered Person” means, with respect to the Company as an
“issuer” for purposes of Rule 506 promulgated under the 1933 Act, any Person listed in the first paragraph of Rule 506(d)(1). 

“Intellectual Property” has the meaning set forth in Section 4.14. 

“Company’s Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933
Act) of the Company. 
 “Control” (including the terms “controlling,” “controlled by” or “under
common control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Disqualification Event” has the meaning set forth in Section 4.33. 

“EDGAR system” has the meaning set forth in Section 4.9. 

“Effective Date” has the meaning set forth in Section 7.4(b). 

“Environmental Laws” has the meaning set forth in Section 4.15. 

“GAAP” has the meaning set forth in Section 4.17. 

“Investor Questionnaire” has the meaning set forth in Section 5.8. 

“Losses” has the meaning set forth in Section 8.2. 

“Material Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations,
financial condition or business of the Company and its subsidiary taken as a whole, (ii) the legality or enforceability of any of the Transaction Documents or (iii) the ability of the Company to perform its obligations under the
Transaction Documents, except that for purposes of Section 6.1(i) of this Agreement, in no event shall a change in the market price of the Common Stock alone constitute a “Material Adverse Effect”. 

“Material Contract” means any contract, instrument or other agreement to which the Company is a party or by which it is bound
that has been filed or was required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K. 

“Nasdaq” means the Nasdaq Global Select Market. 

“Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint
stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

  
 2 

 “Press Release” has the meaning set forth in Section 9.7. 

“Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall be the Nasdaq Global Select Market. 
 “Registration Rights
Agreement” has the meaning set forth in the recitals to this Agreement. 
 “Regulation D” has the meaning set
forth in the recitals to this Agreement. 
 “Regulatory Authorities” has the meaning set forth in Section 4.30. 

“Required Investors” has the meaning set forth in the Registration Rights Agreement. 

“SEC” means the U.S. Securities and Exchange Commission. 

“SEC Filings” has the meaning set forth in Section 4.8. 

“Shares” has the meaning set forth in the recitals to this Agreement. 

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be
deemed to include the location and/or reservation of borrowable shares of Common Stock). 
 “Trading Day” means (i) a
day on which the Common Stock is listed or quoted and traded on its Principal Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on which
the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market,
a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets” by OTC Markets Group Inc. (or any similar
organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) or (iii) hereof, then Trading Day shall mean a Business Day. 

“Trading Market” means whichever of the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the
Nasdaq Global Market, the Nasdaq Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 

“Transfer Agent” has the meaning set forth in Section 7.4(a). 

“Transaction Documents” means this Agreement and the Registration Rights Agreement. 

  
 3 

 “1933 Act” means the Securities Act of 1933, as amended, or any successor
statute, and the rules and regulations promulgated thereunder. 
 “1934 Act” means the Securities Exchange Act of 1934, as
amended, or any successor statute, and the rules and regulations promulgated thereunder. 
 2. Purchase and Sale of the Shares.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company will issue and sell, and the Investors will purchase, severally and not jointly, the number of Shares set forth opposite the name of such Investor under
the heading “Number of Shares to be Purchased” on Exhibit A attached hereto The purchase price per Share shall be $8.50. 

3. Closing. 

3.1. Upon the satisfaction of the conditions set forth in Section 6, the completion of the purchase and sale
of the Shares (the “Closing”) shall occur remotely via exchange of documents and signatures at a time (the “Closing Date”) to be agreed to by the Company and the Investors but (i) in no event earlier than the
second Business Day after the date hereof and (ii) in no event later than the fifth Trading Day after the date hereof, and of which the Investors will be notified in advance by the Company. 

3.2. On the Closing Date, each Investor shall deliver or cause to be delivered to the Company, via wire transfer of immediately
available funds pursuant to the wire instructions delivered to such Investor by the Company on or prior to the Closing Date, an amount equal to the purchase price to be paid by the Investor for the Shares to be acquired by it as set forth opposite
the name of such Investor under the heading “Aggregate Purchase Price of Shares” on Exhibit A attached hereto. 
 3.3.
At or before the Closing, the Company shall deliver or cause to be delivered to each Investor a number of Shares, registered in the name of the Investor (or its nominee in accordance with its delivery instructions), equal to the number of Shares
set forth opposite the name of such Investor under the heading “Number of Shares to be Purchased” on Exhibit A attached hereto. The Shares shall be delivered via a book-entry record through the Company’s transfer agent. Unless
the Company and an Investor otherwise mutually agree with respect to such Investor’s Shares, at Closing settlement shall occur on a “delivery versus payment” basis. 

4. Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors that, except
(a) as described in the Company’s SEC Filings (as defined below) and (b) as set forth on the disclosure schedule delivered herewith (which is arranged in numbered and lettered sections corresponding to the numbered and lettered
sections contained in this Section 4) (the “Disclosure Schedule”), each of which qualify these representations and warranties in their entirety: 

4.1. Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own or lease its properties. The Company is duly qualified to

  
 4 

 
do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing
necessary unless the failure to so qualify has not had and would not reasonably be expected to have a Material Adverse Effect. The Company’s subsidiary is set forth on Exhibit 21.1 to its most recent Annual Report on Form 10-K, and the Company owns 100% of the outstanding equity securities of such subsidiary. The Company’s subsidiary is duly organized, validly existing and in good standing under the laws of the Commonwealth of
Massachusetts and has all requisite power and authority to carry on their business as now conducted and to own or lease its properties. The Company’s subsidiary is duly qualified to do business as a foreign corporation and is in good standing
in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and would not reasonably be expected to have a Material
Adverse Effect. 
 4.2. Authorization. The Company has the requisite corporate power and authority and has taken all requisite
corporate action necessary for, and no further action on the part of the Company, its officers, directors and stockholders is necessary for, (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization
of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Shares. The Transaction Documents constitute the legal, valid and binding
obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting
creditors’ rights generally and to general equitable principles. 
 4.3. Capitalization. The Company is authorized under
its Certificate of Incorporation to issue 200,000,000 shares of Common Stock. The Company’s disclosure of its issued and outstanding capital stock in its most recent SEC Filing containing such disclosure was accurate in all material respects as
of the date indicated in such SEC Filing. All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued and are fully paid and nonassessable; none of such shares were issued in violation of
any preemptive rights; and such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties. No Person is entitled to preemptive or similar statutory or contractual
rights with respect to the issuance by the Company of any securities of the Company, including, without limitation, the Shares. Except as described in the SEC Filings, there are no outstanding warrants, options, convertible securities or other
rights, agreements or arrangements of any character under which the Company is or may be obligated to issue any equity securities of any kind, except as contemplated by this Agreement. There are no voting agreements,
buy-sell agreements, option or right of first purchase agreements or other similar agreements among the Company and any of the securityholders of the Company relating to the securities of the Company held by
them. Except as provided in the Registration Rights Agreement, and except as provided in that certain Fifth Amended and Restated Investor Rights Agreement, dated as of March 22, 2018, by and among the Company and certain investors signatory
thereto, no Person has the right to (i) require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection with the registration of securities of the Company for its own account or for
the account of any other Person or (ii) to prohibit the Company from filing a registration statement under the 1933 Act. 

  
 5 

 The issuance and sale of the Shares hereunder will not obligate the Company to issue shares
of Common Stock or other securities to any other Person (other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security. 

The Company does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect giving any
Person the right to purchase any equity interest in the Company upon the occurrence of certain events. 
 4.4. Valid Issuance.
The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those
created by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. 

4.5. Consents. Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof,
the execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Shares require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official
other than (a) filings that have been made pursuant to applicable state securities laws, (b) post-sale filings pursuant to applicable state and federal securities laws, (c) filings pursuant to the rules and regulations of Nasdaq and
(d) filing of the registration statement required to be filed by the Registration Rights Agreement, each of which the Company has filed or undertakes to file within the applicable time. Subject to the accuracy of the representations and
warranties of each Investor set forth in Section 5 hereof, the Company has taken all action necessary to exempt (i) the issuance and sale of the Shares and (ii) the other transactions contemplated by the Transaction Documents from the
provisions of any stockholder rights plan or other “poison pill” arrangement, any anti-takeover, business combination or control share law or statute binding on the Company or to which the Company or any of its assets and properties is
subject that is or could reasonably be expected to become applicable to the Investors as a result of the transactions contemplated hereby, including without limitation, the issuance of the Shares and the ownership, disposition or voting of the
Shares by the Investors or the exercise of any right granted to the Investors pursuant to this Agreement or the other Transaction Documents. 

4.6. Use of Proceeds. The net proceeds of the sale of the Shares hereunder shall be used by the Company for working capital and
general corporate purposes. 
 4.7. No Material Adverse Change. Since June 30, 2019, except as identified and described in
the SEC Filings filed at least one Trading Day prior to the date hereof, there has not been: 
 (i) any change in the consolidated
assets, liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended
June 30, 2019, except for changes in the ordinary course of business which have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 

  
 6 

 (ii) any declaration or payment by the Company of any dividend, or any authorization
or payment by the Company of any distribution, on any of the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company; 

(iii) any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company; 

(iv) any waiver, not in the ordinary course of business, by the Company of a material right or of a material debt owed to it; 

(v) any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company, except in the ordinary
course of business and which is not material to the assets, properties, financial condition, operating results or business of the Company (as such business is presently conducted); 

(vi) any change or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to any material contract
or arrangement by which the Company is bound or to which any of its assets or properties is subject; 
 (vii) any material labor
difficulties or, to the Company’s Knowledge, labor union organizing activities with respect to employees of the Company; 
 (viii)
any material transaction entered into by the Company other than in the ordinary course of business; 
 (ix) the loss of the
services of any key employee, or material change in the composition or duties of the senior management of the Company; or 
 (x) any
other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect. 
 4.8.
SEC Filings. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the 1933 Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the
one year period preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (collectively, the “SEC Filings”). At the time of filing thereof, the SEC Filings complied in
all material respects with the requirements of the 1933 Act or the 1934 Act, as applicable, and the rules and regulations of the SEC thereunder. 

4.9. No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by the
Company and the issuance and sale of the Shares in accordance with the provisions thereof will not, except (solely in the case of clauses (i)(b) and (ii)) for such violations, conflicts or defaults as would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect, (i) conflict with or result in a 

  
 7 

 
breach or violation of (a) any of the terms and provisions of, or constitute a default under, the Company’s Certificate of Incorporation or the Company’s Bylaws, both as in effect
on the date hereof (true and complete copies of which have been made available to the Investors through the Electronic Data Gathering, Analysis, and Retrieval system (the “EDGAR system”)), or (b) assuming the accuracy of the
representations and warranties in Section 5, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company or its subsidiary, or any of their assets
or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon any of the
properties or assets of the Company or its subsidiary or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract. This Section does not relate to
matters with respect to tax status, which are the subject of Section 4.10, employee relations and labor matters, which are the subject of Section 4.13, or environmental laws, which are the subject of Section 4.15. 

4.10. Tax Matters. The Company and its subsidiary have timely prepared and filed all material tax returns required to have been
filed by them with all appropriate governmental agencies and timely paid all material taxes shown thereon or otherwise owed by them. There are no material unpaid assessments against the Company nor, to the Company’s Knowledge, any audits
by any federal, state or local taxing authority. All material taxes that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when
due. There are no tax liens pending or, to the Company’s Knowledge, threatened against the Company or any of its assets or property. With the exception of agreements or other arrangements that are not primarily related to taxes
entered into in the ordinary course of business, there are no outstanding tax sharing agreements or other such arrangements between the Company and any other corporation or entity (other than a subsidiary of the Company). 

4.11. Title to Properties. The Company and its subsidiary have good and marketable title to all real properties and all other
properties and assets owned by them, in each case free from liens, encumbrances and defects, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and the Company and its subsidiary
hold any leased real or personal property under valid and enforceable leases with no exceptions, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

4.12. Certificates, Authorities and Permits. The Company possesses adequate certificates, authorities or permits issued by
appropriate governmental agencies or bodies necessary to conduct the business now operated by it, except where failure to so possess would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. The
Company has not received any written notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that would reasonably be expected to have a Material Adverse Effect, individually or in the aggregate,
on the Company. 

  
 8 

 4.13. Labor Matters. 

(a) The Company is not party to or bound by any collective bargaining agreements or other agreements with labor organizations. To the
Company’s Knowledge, the Company has not violated in any material respect any laws, regulations, orders or contract terms affecting the collective bargaining rights of employees or labor organizations, or any laws, regulations or orders
affecting employment discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours. 
 (b)
No material labor dispute with the employees of the Company, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the Company’s Knowledge, is threatened or imminent. 

4.14. Intellectual Property. The Company and its subsidiary own, possess, license or have other rights to use, all patents,
patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual property
(collectively, the “Intellectual Property”) necessary for the conduct of the Company’s business in all material respects as now conducted or as proposed in the SEC Filings to be conducted; and (a) there are no rights of
third parties to any such Intellectual Property, including no liens, security interests or other encumbrances; (b) to the Company’s Knowledge, there is no material infringement by third parties of any such Intellectual Property;
(c) there is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s rights in or to any such Intellectual Property, and, except as would not reasonably be expected
to have a Material Adverse Effect, the Company is aware of no factual basis for any such claim; (d) such Intellectual Property has not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part;
(e) there is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property, including interferences, oppositions, reexaminations or
government proceedings, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (f) there is no pending or threatened action, suit, proceeding or claim by others that the Company infringes,
misappropriates, or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others, and, except as would not reasonably be expected to have a Material Adverse Effect, the Company is unaware of any other fact
with would form a reasonable basis for any such claim; (g) each employee of the Company has entered into an invention assignment agreement with the Company and no employee of the Company is or has been in violation of any term of any employment
contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive
covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company; (h) to the Company’s Knowledge, there is no patent or published patent application in the United States or
other jurisdiction which contains valid claims that dominate any product candidate of the Company described in the SEC Filings; and (i) except as would not reasonably be expected to have a Material Adverse Effect, the Company is not aware of
any prior art that may render U.S. patent held by the Company invalid or any U.S. patent application held by the Company un-patentable which has not been disclosed to the U.S. Patent and Trademark Office and
all such prior art has been disclosed to the patent office or other jurisdiction where required. The Company has complied in all material respects with all license agreements to which it is a party relating to the Intellectual Property and has not
received any asserted or threatened claim of breach of any of the same. 

  
 9 

 4.15. Environmental Matters. The Company is not in violation of any statute,
rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or
human exposure to hazardous or toxic substances (collectively, “Environmental Laws”), has not released any hazardous substances regulated by Environmental Law onto any real property that it owns or operates and has not received any
written notice or claim it is liable for any off-site disposal or contamination pursuant to any Environmental Laws, which violation, release, notice, claim, or liability would reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect, and to the Company’s Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim. 

4.16. Legal Proceedings. There are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to
which the Company or its subsidiary are or may reasonably be expected to become a party or to which any property of the Company or its subsidiary are or may reasonably be expected to become the subject that, individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect. 
 4.17. Financial Statements. The financial statements included in
each SEC Filing comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and
present fairly, in all material respects, the consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown, subject in the case of unaudited financial statements
to normal, immaterial year-end audit adjustments, and such consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (“GAAP”) (except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and, in the case of quarterly
financial statements, except as permitted by Form 10-Q under the 1934 Act). Except as set forth in the financial statements of the Company included in the SEC Filings filed prior to the date hereof, the
Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of which,
individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. 
 4.18. Insurance
Coverage. The Company maintains in full force and effect insurance coverage that is customary for comparably situated companies for the business being conducted and properties owned or leased by the Company, and the Company reasonably believes
such insurance coverage to be adequate against all liabilities, claims and risks against which it is customary for comparably situated companies to insure. 

  
 10 

 4.19. Compliance with Nasdaq Continued Listing Requirements. The Company is in
compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company
has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq. 

4.20. Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any
valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company. No Investor shall have any
obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 4.20 that may be due in connection with the transactions contemplated by
this Agreement or the Transaction Documents. 
 4.21. No Directed Selling Efforts or General Solicitation. Neither the Company
nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D promulgated under the 1933 Act) in connection with the offer or sale of any of the Shares. 

4.22. No Integrated Offering. Neither the Company nor its subsidiary nor any Person acting on their behalf has, directly or
indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) and Regulation D for the exemption from
registration for the transactions contemplated hereby or would require registration of the Shares under the 1933 Act. 
 4.23.
Private Placement. Assuming the accuracy of the representations and warranties of the Investors set forth in Section 5, the offer and sale of the Shares to the Investors as contemplated hereby is exempt from the registration
requirements of the 1933 Act. The issuance and sale of the Shares does not contravene the rules and regulations of Nasdaq. 
 4.24.
Questionable Payments. Neither the Company nor its subsidiary nor, to the Company’s Knowledge, any of their current or former directors, officers, employees, agents or other Persons acting on behalf of the Company or its subsidiary,
has on behalf of the Company or its subsidiary in connection with their business: (a) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct
or indirect unlawful payments to any governmental officials or employees from corporate funds; (c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets which is in violation of law; (d) made any
false or fictitious entries on the books and records of the Company; or (e) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any nature. 

4.25. Transactions with Affiliates. None of the executive officers or directors of the Company and, to the Company’s
Knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than as holders of stock options, warrants and/or restricted stock, and for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the
Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 

  
 11 

 4.26. Internal Controls. The Company has established and maintains disclosure
controls and procedures (as defined in Rules 13a-15 and 15d-15 under the 1934 Act), which are designed to ensure that material information relating to the Company,
including its subsidiary, is made known to the Company’s principal executive officer and its principal financial officer by others within those entities. Since the end of the Company’s most recent audited fiscal year, there have been no
material weaknesses in the Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or would reasonably be
expected to materially affect, the Company’s internal control over financial reporting. The Company is not aware of any change in its internal controls over financial reporting that has occurred during its most recent fiscal quarter that has
materially affected, or would reasonably be expected to materially affect, the Company’s internal control over financial reporting. 

4.27. Disclosures. Neither the Company nor any Person acting on its behalf has provided the Investors or their agents or counsel
with any information that constitutes or would reasonably be expected to constitute material nonpublic information concerning the Company or its subsidiary, other than (A) with respect to the transactions contemplated hereby, which will be
disclosed in the Press Release (as defined below) and (B) as set forth on the Disclosure Schedule. The SEC Filings do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
contained therein, in light of the circumstances under which they were made, not misleading. The Company understands and confirms that the Investors will rely on the foregoing representations in effecting transactions in securities of the
Company.
 4.28. Required Filings. Except for the transactions contemplated by this Agreement, including the acquisition of the
Shares contemplated hereby, no event or circumstance has occurred or information exists with respect to the Company or its business, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public
disclosure or announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the SEC Filings are being incorporated by reference into an effective registration statement filed by the Company
under the 1933 Act). 
 4.29. Investment Company. The Company is not required to be registered as, and immediately following
the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 

4.30. Tests and Preclinical and Clinical Trials. (i) The preclinical studies and clinical trials conducted by or on behalf
of or sponsored by the Company or its subsidiary, or in which the Company or its subsidiary have participated, that are described in the SEC Filings, or the results of which are referred to in the SEC Filings, as applicable, were, and if still
pending are, being conducted in all material respects in accordance with standard medical and scientific research standards and procedures for products or product candidates comparable to those being

  
 12 

 
developed by the Company and in material compliance with all statutes and all applicable rules and regulations of the U.S. Food and Drug Administration (the “FDA”) and other
comparable regulatory authorities (including, without limitation, any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) to which they are subject (collectively, the
“Regulatory Authorities”) and current Good Clinical Practices and Good Laboratory Practices; (ii) except as set forth on the Disclosure Schedule, the descriptions in the SEC Filings of the results of such studies and trials are
accurate and complete descriptions in all material respects and fairly present the data derived therefrom; (iii) to the Company’s Knowledge, there are no other studies or trials not described in the SEC Filings, the results of which the
Company believes are inconsistent with or reasonably call into question the results described or referred to in the SEC Filings; (iv) the Company and its subsidiary have operated at all times and are currently in compliance with all applicable
statutes, rules and regulations of the Regulatory Authorities; and (v) neither the Company nor any of its subsidiary have received any written notices, correspondence or other communications from the Regulatory Authorities or any other
governmental agency requiring or threatening the termination, material modification or suspension of any preclinical studies or clinical trials that are described in the SEC Filings or the results of which are referred to in the SEC Filings, other
than ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to the Company’s Knowledge, there are no reasonable grounds for the same. 

4.31. Manipulation of Price. The Company has not taken, and, to the Company’s Knowledge, no Person acting on its behalf
has taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares. 

4.32. Anti-Bribery and Anti-Money Laundering Laws. Each of the Company, its subsidiary and any of their respective officers,
directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws, including but not limited to, any applicable law, rule, or
regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17,
1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope or (B) anti-money laundering laws, including, but not limited to,
applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and
international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United
States representative to the group or organization continues to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder. 

4.33. No Bad Actors. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the 1933 Act (a
“Disqualification Event”) is applicable to the Company or, to the Company’s Knowledge, any Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3) is applicable. 

  
 13 

 4.34. No Additional Agreements. The Company has no other agreements or
understandings (including, without limitation, side letters) with any Investor to purchase Shares on terms more favorable to such Investor than as set forth herein. 

4.35. Shell Company Status. The Company is not, and has never been, an issuer identified in Rule 144(i)(1). 

4.36. Compliance. The Company is not (i) in default under or in violation of (and no event has occurred that has not
been waived that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit
agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived) or (ii) in violation of any judgment, decree or order of any
court, arbitrator or governmental body, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect. 

5. Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly, represents and
warrants to the Company that: 
 5.1. Organization and Existence. Such Investor is a duly incorporated or organized and validly
existing corporation, limited partnership, limited liability company or other legal entity, has all requisite corporate, partnership or limited liability company power and authority to enter into and consummate the transactions contemplated by the
Transaction Documents and to carry out its obligations hereunder and thereunder, and to invest in the Shares pursuant to this Agreement, and is in good standing under the laws of the jurisdiction of its incorporation or organization. 

5.2. Authorization. The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor
is a party have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in accordance with their respective terms, subject
to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally, and general principles of equity. 

5.3. Purchase Entirely for Own Account. The Shares to be received by such Investor hereunder will be acquired for such
Investor’s own account, not as nominee or agent, for the purpose of investment and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and such Investor has no present intention of selling, granting
any participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of all or any part of such Shares in compliance with applicable
federal and state securities laws. The Shares are being purchased by such Investor in the ordinary course of its business. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Shares for any period of
time. Such Investor is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered. 

  
 14 

 5.4. Investment Experience. Such Investor acknowledges that it can bear the
economic risk and complete loss of its investment in the Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby. 

5.5. Disclosure of Information. Such Investor has had an opportunity to receive, review and understand all information related
to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares, and has conducted and completed its own independent due
diligence. Such Investor acknowledges that copies of the SEC Filings are available on the EDGAR system. Based on the information such Investor has deemed appropriate, it has independently made its own analysis and decision to enter into the
Transaction Documents. Such Investor is relying exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and performance of the Transaction Documents,
the Shares and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all business, legal, regulatory, accounting, credit and tax matters. Neither such
inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect such Investor’s right to rely on the Company’s representations and warranties contained in this Agreement. 

5.6. Restricted Securities. Such Investor understands that the Shares are characterized as “restricted securities”
under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under
the 1933 Act only in certain limited circumstances. 
 5.7. Legends. It is understood that, except as provided below,
certificates or book-entry records evidencing the Shares may bear the following or any similar legend: 
 (a) “The securities
represented hereby have not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not
be transferred unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, (ii) such securities may be sold pursuant to Rule 144, (iii) the Company has received an opinion of
counsel reasonably satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933, as amended, or (iv) the securities are transferred without consideration to an affiliate of such holder or a
custodial nominee (which for the avoidance of doubt shall require neither consent nor the delivery of an opinion).” 
 (b) If
required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by such state authority. 

  
 15 

 5.8. Accredited Investor. Such Investor is (a) an “accredited
investor” within the meaning of Rule 501(a) of Regulation D. Such Investor has executed and delivered to the Company a questionnaire in substantially the form attached hereto as Exhibit C (the “Investor Questionnaire”),
which such Investor represents and warrants is true, correct and complete. Such investor is a sophisticated institutional investor with sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks
and merits of its purchase of the Shares. Such Investor has determined based on its own independent review and such professional advice as it deems appropriate that its purchase of the Shares and participation in the transactions contemplated by the
Transaction Documents (i) are fully consistent with its financial needs, objectives and condition, (ii) comply and are fully consistent with all investment policies, guidelines and other restrictions applicable to such Investor,
(iii) have been duly authorized and approved by all necessary action, (iv) do not and will not violate or constitute a default under such Investor’s charter, bylaws or other constituent document or under any law, rule, regulation,
agreement or other obligation by which such Investor is bound and (v) are a fit, proper and suitable investment for such Investor, notwithstanding the substantial risks inherent in investing in or holding the Shares. 

5.9. No General Solicitation. Such Investor did not learn of the investment in the Shares as a result of any general or public
solicitation or general advertising, or publicly disseminated advertisements or sales literature, including (a) any advertisement, article, notice or other communication published in any newspaper, magazine, website, or similar media, or
broadcast over television or radio, or (b) any seminar or meeting to which such Investor was invited by any of the foregoing means of communications. 

5.10. Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any
valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor. 

5.11. Short Sales and Confidentiality Prior to the Date Hereof. Other than consummating the transactions contemplated hereunder,
such Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period
commencing as of the time that such Investor was first contacted by the Company or any other Person regarding the transactions contemplated hereby and ending immediately prior to the date hereof. Notwithstanding the foregoing, in the case of an
Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Investor’s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Shares
covered by this Agreement. Other than to other Persons party to this Agreement and other than to such Person’s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment,
and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law, such Investor has maintained the confidentiality of all disclosures made to it in
connection with this transaction (including the existence and terms of this transaction). 

  
 16 

 Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a
representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. 

5.12. No Government Recommendation or Approval. Such Investor understands that no United States federal or state agency, or
similar agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of the Shares. 

5.13. No Intent to Effect a Change of Control. Such Investor has no present intent to effect a “change of control” of
the Company as such term is understood under the rules promulgated pursuant to Section 13(d) of the 1934 Act. 
 5.14.
Residency. Such Investor’s office in which its investment decision with respect to the Shares was made is located at the address immediately below such Investor’s name on its signature page hereto. 

5.15. No Conflicts. The execution, delivery and performance by such Investor of the Transaction Documents and the consummation by
such Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of
time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Investor, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Investor to perform its obligations hereunder. 

6. Conditions to Closing. 

6.1. Conditions to the Investors’ Obligations. The obligation of each Investor to purchase Shares at the Closing is subject
to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to itself only): 

(a) The representations and warranties made by the Company in Section 4 hereof shall be true and correct as of the date hereof and
as of the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such
earlier date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date. 

(b) The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation
of the purchase and sale of the Shares and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect. 

  
 17 

 (c) The Company shall have executed and delivered the Registration Rights Agreement.

 (d) The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares, and
the Company shall not have received an objection thereto from Nasdaq. 
 (e) No judgment, writ, order, injunction, award or decree of
or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental
authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents. 
 (f)
The Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in
subsections (a), (b), (d), (e) and (j) of this Section 6.1. 
 (g) The Company shall have delivered a Certificate, executed
on behalf of the Company by its Secretary, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement, the other Transaction Documents and the
issuance of the Shares, certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of
the Company. 
 (h) The Investors shall have received an opinion from Wilmer Cutler Pickering Hale and Dorr LLP, the Company’s
counsel, dated as of the Closing Date, in form and substance reasonably acceptable to the Investors and addressing such legal matters as the Investors may reasonably request. 

(i) There shall have been no Material Adverse Effect with respect to the Company since the date hereof. 

(j) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with
respect to public trading in the Common Stock. 
 6.2. Conditions to Obligations of the Company. The Company’s obligation
to sell and issue the Shares at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: 

(a) The representations and warranties made by the Investors in Section 5 hereof shall be true and correct as of the date hereof,
and shall be true and correct as of the Closing Date with the same force and effect as if they had been made on and as of such date. The Investors shall have performed in all material respects all obligations and covenants herein required to be
performed by them on or prior to the Closing Date. 

  
 18 

 (b) The Investors shall have executed and delivered the Registration Rights Agreement
and each Investor Questionnaire. 
 (c) Any Investor purchasing Shares at the Closing shall have paid in full its purchase price to
the Company. 
 6.3. Termination of Obligations to Effect Closing; Effects. 

(a) The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as
follows: 
 (i) Upon the mutual written consent of the Company and Investors that agreed to purchase a majority of the Shares to be
issued and sold pursuant to this Agreement; 
 (ii) By the Company if any of the conditions set forth in Section 6.2 shall have
become incapable of fulfillment, and shall not have been waived by the Company; 
 (iii) By an Investor (with respect to itself only)
if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived by the Investor; or 

(iv) By either the Company or any Investor (with respect to itself only) if the Closing has not occurred on or prior to the fifth
Trading Day following the date of this Agreement; 
 provided, however, that, except in the case of clause (i) above, the party seeking to terminate its
obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving
rise to such party’s seeking to terminate its obligation to effect the Closing. 
 (b) In the event of termination by the Company
or any Investor of its obligations to effect the Closing pursuant to this Section 6.3, written notice thereof shall be given to the other Investors by the Company and the other Investors shall have the right to terminate their obligations to
effect the Closing upon written notice to the Company and the other Investors. Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the
other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. 

7. Covenants and Agreements of the Company. 

7.1. No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would
conflict or interfere in any material respect with the Company’s obligations to the Investors under the Transaction Documents. 

  
 19 

 7.2. Compliance with Laws. The Company will comply in all material respects
with all applicable laws, rules, regulations, orders and decrees of all governmental authorities. 
 7.3. Nasdaq Listing. The
Company will use commercially reasonable efforts to continue the listing and trading of its Common Stock on Nasdaq and, in accordance therewith, will use commercially reasonable efforts to comply in all material respects with the Company’s
reporting, filing and other obligations under the bylaws or rules of such market or exchange, as applicable. 
 7.4. Reporting
Status. The Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the
rules and regulations thereunder would otherwise permit such termination. 
 7.5. Termination of Covenants. The provisions of
Sections 7.1 through 7.4 shall terminate and be of no further force and effect on the date on which the Company’s obligations under the Registration Rights Agreement to register or maintain the effectiveness of any registration covering
the Registrable Securities (as such term is defined in the Registration Rights Agreement) shall terminate. 
 7.6. Removal of
Legends. 
 (a) In connection with any sale, assignment, transfer or other disposition of the Shares by an Investor pursuant to
Rule 144 or pursuant to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor, the Company shall
request the transfer agent for the Common Stock (the “Transfer Agent”) to remove any restrictive legends related to the book-entry account holding such Shares and make a new, unlegended entry for such book-entry shares sold or
disposed of without restrictive legends within two (2) Trading Days of any such request therefor from such Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably
acceptable to the Company in connection therewith. 
 (b) Subject to receipt from the Investor by the Company and the Transfer Agent
of customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares (i) have been sold or transferred pursuant to an effective
registration statement, (ii) have been sold pursuant to Rule 144, or (iii) are eligible for resale under Rule 144(b)(1) or any successor provision (such earliest date, the “Effective Date”), the Company shall, in
accordance with the provisions of this Section 7.6(b) and within two (2) Trading Days of any request therefor from an Investor accompanied by such customary and reasonably acceptable documentation referred to above, (A) deliver to the
Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book-entry Shares, and (B) cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of
such legends in such circumstances may be effected under the 1933 Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of 

  
 20 

 
this Agreement. The Company agrees that following the Effective Date or at such time as such legend is no longer required under this Section 7.6, it will, within two Trading Days of the
delivery by an Investor to the Company or the Transfer Agent of a certificate representing shares issued with a restrictive legend and receipt from the Investor by the Company and the Transfer Agent of customary representations and other
documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, deliver or cause to be delivered to such Investor a certificate representing such Shares (or uncertificated interest therein) that is free from all
restrictive and other legends. Shares subject to legend removal hereunder may be transmitted by the Transfer Agent to the Investor by crediting the account of the Investor’s prime broker with the DTC System as directed by such Investor. The
Company shall be responsible for the fees of its Transfer Agent and all DTC fees associated with such issuance. 
 (c) Each Investor,
severally and not jointly with the other Investors, agrees with the Company (i) that such Investor will sell any Shares only pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery
requirements, or an exemption therefrom, (ii) that if Shares are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein and (iii) that if, after the effective date of the
registration statement covering the resale of the Shares, such registration statement ceases to be effective and the Company has provided notice to such Investor to that effect, such Investor will sell Shares only in compliance with an exemption
from the registration requirements of the 1933 Act. 
 7.7. Subsequent Equity Sales. 

(a) From the date hereof until seventy-five (75) days after the Closing Date, without the consent of the Required Investors, the
Company shall not (A) issue shares of Common Stock or Common Stock Equivalents, (B) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Stock or
(C) file with the SEC a registration statement under the 1933 Act relating to any shares of Common Stock or Common Stock Equivalents, except pursuant to the terms of the Registration Rights Agreement. Notwithstanding the foregoing, the
provisions of this Section 7.7 shall not apply to (i) the issuance of the Shares hereunder, (ii) the issuance of Common Stock or Common Stock Equivalents upon the conversion or exercise of any securities of the Company outstanding on
the date hereof or outstanding pursuant to clause (iii) or (v) below, (iii) the issuance of any Common Stock or Common Stock Equivalents pursuant to any Company stock-based compensation plans or in accordance with Nasdaq Stock Market Rule
5635(c)(4), (iv) the filing of a registration statement on Form S-8 under the 1933 Act to register the offer and sale of securities on an equity incentive plan or employee stock purchase plan or (v) the
issuance of any Common Stock or Common Stock Equivalents in connection with a transaction with unaffiliated third party that includes a debt financing or a bona fide commercial relationship (including joint ventures, marketing or distribution
arrangements, collaboration agreements or intellectual property license agreements) or any acquisition of assets or acquisition of not less than a majority or controlling portion of the equity of another entity); provided, however, that the
aggregate number of shares of Common Stock issued pursuant to clause (v) during the restricted period shall not exceed 10% of the total number of shares of Common Stock issued and outstanding immediately following the Closing. 

  
 21 

 (b) The Company shall not, and shall use its commercially reasonable efforts to
ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated with the offer or sale of the
Shares in a manner that would require the registration under the 1933 Act of the sale of the Shares to the Investors, or that will be integrated with the offer or sale of the Shares for purposes of the rules and regulations of any trading market
such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. 

7.8. Fees. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or
broker’s commissions (other than for Persons engaged by any Investor) relating to or arising out of the transactions contemplated hereby. 

7.9. Short Sales and Confidentiality After the Date Hereof. Each Investor covenants that neither it nor any Affiliates acting on
its behalf or pursuant to any understanding with it will trade in the securities of the Company and will not execute any Short Sales during the period from the date hereof until the earlier of such time as both (i) the transactions contemplated
by this Agreement and (ii) all material information set forth in the Disclosure Schedule have been publicly disclosed by the Company. Each Investor understands and acknowledges that the SEC currently takes the position that coverage of Short
Sales of shares of the Common Stock “against the box” prior to effectiveness of a resale registration statement with securities included in such registration statement would be a violation of Section 5 of the 1933 Act, as set forth in
Item 239.10 of the Securities Act Rules Compliance and Disclosure Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance. Each Investor covenants that until such time (i) as all material terms of the sale of
the Shares to the Investors pursuant to this Agreement have been publicly disclosed by the Company, such Investor and its Affiliates will maintain the confidentiality of the existence and terms of this Agreement and (ii) as all material
information set forth in the Disclosure Schedule have been publicly disclosed by the Company, such Investor and its Affiliates will maintain the confidentiality of all information included on the Disclosure Schedule, in each case other than to such
Person’s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative
tasks and services and other than as may be required by law. 
 8. Survival and Indemnification. 

8.1. Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing of
the transactions contemplated by this Agreement for the applicable statute of limitations. 
 8.2. Indemnification. The Company
agrees to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, members, managers, employees, investment advisers and agents, from and against any and all losses, claims, damages,
liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably
incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”)

  
 22 

 
to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction
Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally judicially determined not to have resulted from such Person’s fraud or willful
misconduct. 
 8.3. Conduct of Indemnification Proceedings. Any person entitled to indemnification hereunder
shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to
the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the
expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to
such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person
notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person);
and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice
shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or
expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or
delayed, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim
or litigation. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. 

9. Miscellaneous. 

9.1. Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the
Company or each of the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Shares in a transaction
complying with applicable securities laws without the prior written consent of the Company or the other Investors, provided such assignee agrees in writing to be bound by the provisions hereof that apply to Investors. The provisions of this
Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Without limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share
exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another Person, from and after the 

  
 23 

 
effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be
deemed to refer to such Person and the term “Shares” shall be deemed to refer to the securities received by the Investors in connection with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

9.2. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or
other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

9.3. Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 
 9.4. Notices. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by
facsimile or e-mail, then such notice shall be deemed given upon receipt of confirmation of complete facsimile transmittal or confirmation of receipt of an e-mail
transmission, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and
(iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows,
or at such other address as such party may designate by ten days’ advance written notice to the other party: 
 If to the Company: 

Constellation Pharmaceuticals, Inc. 

215 First Street, Suite 200 

Cambridge, MA 02142 
 Attention:
Karen Valentine, Chief Legal Officer & General Counsel 
 Email: Karen.Valentine@constellationpharma.com 

With a copy (which shall not constitute notice) to: 

Wilmer Cutler Pickering Hale and Dorr LLP 

60 State Street 
 Boston,
Massachusetts 02109 
 Attention: Lia Der Marderosian 

Email: Lia.DerMarderosian@wilmerhale.com 

  
 24 

 If to the Investors: 

Only to the addresses set forth on the signature pages hereto. 

9.5. Expenses. At the Closing, the Company shall pay the reasonable expenses of Cooley LLP, the counsel for Venrock Healthcare
Capital Partners, III L.P., in an amount not to exceed, in the aggregate, $75,000. 
 9.6. Amendments and Waivers. Prior to
Closing, no amendment or waiver of any provision of this Agreement will be effective with respect to any party unless made in writing and signed by a duly authorized representative of such party. Following the Closing, any term of this Agreement may
be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Required Investors.
Notwithstanding the foregoing, this Agreement may not be amended and the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to
all Investors in the same fashion. Any amendment or waiver effected in accordance with this paragraph shall be binding upon (i) prior to Closing, each Investor that signed such amendment or waiver and (ii) following the Closing, each
holder of any Shares purchased under this Agreement at the time outstanding, and in each case, each future holder of all such Shares and the Company. 

9.7. Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated hereby
shall be issued by the Investors without the prior consent of the Company, except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the
Investors shall allow the Company reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding the foregoing, each Investor may identify the Company and the value of such Investor’s security holdings
in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies without prior notice to or consent from the Company (including, for the avoidance of doubt, filings pursuant to Sections 13 and 16 of
the 1934 Act). The Company shall not include the name of any Investor or any Affiliate or investment adviser of such Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any SEC Filing to the
extent such disclosure is required by SEC rules and regulations) without the prior written consent of such Investor. By 8:30 a.m. (New York City time) on the Business Day immediately following the date this Agreement is executed, the Company shall
issue a press release disclosing all material terms of the sale of the Shares to the Investors pursuant to this Agreement (the “Press Release”). No later than seventy five (75) days after the Closing Date, the Company shall
issue a press release and/or a Current Report on Form 8-K disclosing any material non-public information that the Company may have provided any Investor in connection
with the transactions contemplated by this Agreement at any time prior to the filing of such press release (the “Cleansing Disclosure”), as such material non-public information may be updated
from time-to-time including through the inclusion of additional data. In addition, the Company will make such other filings and notices in the manner and time required
by the SEC or Nasdaq. From and after the issuance of the Cleansing Disclosure, no Investor shall be in possession of any material non-public information received from the Company, its subsidiary or any of
their respective officers, directors, employees or agents in connection with the transactions contemplated by this Agreement. 

  
 25 

 9.8. Severability. Any provision of this Agreement that is prohibited or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be
enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by
applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect. 

9.9. Entire Agreement. This Agreement, including the signature pages, Exhibits, the other Transaction Documents and the
Confidentiality Agreement between the Company and each Investor constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and
written, between the parties with respect to the subject matter hereof and thereof. 
 9.10. Further Assurances. The parties
shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.

 9.11. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New
York. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. 

9.12. Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any Transaction
Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Transaction Document. The decision of each Investor
to purchase Shares pursuant to the Transaction Documents has been made by such Investor independently of any other Investor. Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be
deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the
transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of such
Investor in connection with monitoring its investment in the Shares or enforcing its rights under the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights
arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the Investors
has been provided with the same Transaction Documents for the purpose of closing 

  
 26 

 
a transaction with multiple Investors and not because it was required or requested to do so by any Investor. It is expressly understood and agreed that each provision contained in this Agreement
is between the Company and an Investor, solely, and not between the Company and the Investors collectively and not between and among the Investors. 

[remainder of page intentionally left blank] 

  
 27 

 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. 
  

							
	COMPANY:	  	                	  	CONSTELLATION PHARMACEUTICAL, INC.
				
		  		  	By:	  	 /s/ Jigar Raythatha

		  		  		  	Name: Jigar Raythatha
		  		  		  	Title: Chief Executive Officer

  

							
	INVESTOR:	 	                	 	Venrock Healthcare Capital Partners, II L.P.
			
		 		 	By: VHCP Management II, LLC
		 		 	Its: General Partner
				
		 		 	By:	  	 /s/ Bong Koh

		 		 	Title:	  	Authorized Signatory

							
	INVESTOR:	  	                	  	VHCP Co-Investment Holdings II, LLC
			
		  		  	By: VHCP Management II, LLC
		  		  	Its: General Partner
				
		  		  	By:	  	 /s/ Bong Koh

		  		  	Title: Authorized Signatory

  
 30 

							
	INVESTOR:	  	                	  	Venrock Healthcare Capital Partners, III L.P.
			
		  		  	By: VHCP Management III, LLC,
		  		  	its general partner
		  		  	By: VR Adviser, LLC, its manager
				
		  		  	By:	  	 /s/ Bong Koh

		  		  	Title: Authorized Signatory

  
 31 

							
	INVESTOR:	 	                	 	VHCP Co-Investment Holdings III, LLC
			
		 		 	By: VHCP Management III, LLC, its manager
		 		 	By: VR Adviser, LLC, its manager
				
		 		 	By:	  	 /s/ Bong Koh

		 		 	Title: Authorized Signatory

  
 32 

							
	INVESTOR:	 	                	 	Bain Capital Life Sciences Fund, L.P.
			
		 		 	By: Bain Capital Life Sciences Partners, LP
		 		 	its general partner
		 		 	By: Bain Capital Life Sciences Investors, LLC
		 		 	its general partner
				
		 		 	By:	  	 /s/ Andrew Hack

		 		 	Name: Andrew Hack
		 		 	Title: Managing Director

  
 33 

							
	INVESTOR:	 	                	 	BCIP Life Sciences Associates, LP
			
		 		 	By: Boylston Coinvestors, LLC
		 		 	its general partner
				
		 		 	By:	  	 /s/ Andrew Hack

		 		 	Name: Andrew Hack
		 		 	Title: Managing Director

  
 34 

							
	INVESTOR:	 	                	 	Ponoi Capital, LP
			
		 		 	By: Ponoi Management, LLC
		 		 	Its: General Partner
				
		 		 	By:	  	 /s/ James Evangelista

		 		 	Name: James Evangelista
		 		 	Title: Chief Financial Officer

  
 35 

					
	INVESTOR:	 	Ponoi Capital II, LP
			
		 	By:	  	Ponoi II Management, LLC
		 	Its:	  	General Partner
			
		 	By:	  	 /s/ James Evangelista

		 	Name: James Evangelista
		 	Title: Chief Financial Officer

  
 36 

					
	INVESTOR:	  	Vivo Opportunity Fund, L.P.
			
		  	By:	  	 /s/ Guarav Aggarwal

		  	Name: Guarav Aggarwal
		  	 Title: Managing Member of Vivo Opportunity,

LLC, General Partner

  
 37 

					
	INVESTOR:	 	Vivo Capital Fund IX, L.P.
			
		 	By:	  	 /s/ Albert Cha

		 	Name: Albert Cha
		 	 Title: Managing Member of Vivo Capital IX, LLC,

General Partner

  
 38 

					
	INVESTOR:	 	David V. and Alena Z. Goeddel 2004 Trust
			
		 	By:	  	 /s/ David V. Goeddel

		 	Name: David V. Goeddel
		 	Title: Trustee

  
 39 

 EXHIBIT A 

Schedule of Investors 
  

									
	 Investor Name
	  	Number of Shares to be
Purchased	 	  	Aggregate Purchase
Price of Shares	 
	 Venrock Healthcare Capital Partners, II L.P.
	  	 	550,770	 	  	$	4,681,545.00	 
	 VHCP Co-Investment Holdings II, LLC
	  	 	223,184	 	  	$	1,897,064.00	 
	 Venrock Healthcare Capital Partners, III L.P.
	  	 	1,863,351	 	  	$	15,838,483.50	 
	 VHCP Co-Investment Holdings III, LLC
	  	 	186,224	 	  	$	1,582,904.00	 
	 Bain Capital Life Sciences Fund, L.P.
	  	 	2,561,350	 	  	$	21,771,475.00	 
	 BCIP Life Sciences Associates, LP
	  	 	262,179	 	  	$	2,228,521.50	 
	 Ponoi Capital, LP
	  	 	665,882	 	  	$	5,659,997.00	 
	 Ponoi Capital II, LP
	  	 	665,882	 	  	$	5,659,997.00	 
	 Vivo Opportunity Fund, L.P.
	  	 	480,519	 	  	$	4,084,411.50	 
	 Vivo Capital Fund IX, L.P.
	  	 	107,716	 	  	$	915,586.00	 
	 David V. and Alena Z. Goeddel 2004 Trust
	  	 	80,000	 	  	$	680,000.00	 
	 TOTAL
	  	 	7,647,057	 	  	$	64,999,984.50	 

  
 40

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]